Document is current

Article History

Received: 15 July 2024

Accepted: 8 October 2024

First Online: 4 November 2024

Declarations

:

: CAFvA received honoraria from serving on the scientific advisory board of Biogen, Roche, Novo Nordisk and Dr. Willmar Schwabe GmbH &Co. and has received funding for travel and speaker honoraria from Biogen, Roche, Novartis, Medical Tribune Verlagsgesellschaft mbH, Landesvereinigung für Gesundheit und Akademie für Sozialmedizin Niedersachsen e. V., FomF GmbH | Forum für medizinische Fortbildung and Dr. Willmar Schwabe GmbH & Co. She has further received research support from Roche diagnostics AG and research funding from the Innovationsfond (Fund of the Federal Joint Committee, Gemeinsamer Bundesausschuss, G-BA Grants No. VF1_2016-201; 01NVF21010; 01VSF21019). All other authors declare no competing interests.

: This study was conducted in accordance with the guidelines for Good Clinical Practice and the Declaration of Helsinki due to ethical principles for medical research involving human subjects. Moreover, it was approved by the Ethics Commission of the Faculty of Medicine of the Eberhard-Karls University and University Hospital Tübingen with number 233/2017BO1 on October 12, 2017 and by the Ethics Commission of the University of Potsdam with number 38/2017 on December 11, 2017. The study was registered on the German Clinical Trials Register (DRKS- ID: DRKS00012797) in July, 2017. All included patients provided their written informed consent to participate in this study.

: All included patients provided their written informed consent to participate in this study.